Events, Circulars & Forms
HUTCHMED announces the NDA for ORPATHYS® and TAGRISSO® combination for EGFR mutation-positive NSCLC with MET amplification has been accepted by China's NMPA, triggering a milestone payment from AstraZeneca. The SACHI trial supports the NDA, showing improved PFS. HUTCHMED and AstraZeneca aim to enhance NSCLC treatment continuity and quality of life.
Related Clinical Trials
Reference News
Events, Circulars & Forms
HUTCHMED announces the NDA for ORPATHYS® and TAGRISSO® combination for EGFR mutation-positive NSCLC with MET amplification has been accepted by China's NMPA, triggering a milestone payment from AstraZeneca. The SACHI trial supports the NDA, showing improved PFS. HUTCHMED and AstraZeneca aim to enhance NSCLC treatment continuity and quality of life.